Association of Rising Cost and Use of Oral Anticancer Drugs With Medicare Part D Spending From 2013 Through 2017

Kira Seiger; Arash Mostaghimi; Ann W Silk; Chrysalyne D Schmults; Emily Stamell Ruiz

doi:10.1001/jamaoncol.2019.4906

Association of Rising Cost and Use of Oral Anticancer Drugs With Medicare Part D Spending From 2013 Through 2017

JAMA Oncol. 2020 Jan 1;6(1):154-156. doi: 10.1001/jamaoncol.2019.4906.

Authors

Kira Seiger^{1

2

3}, Arash Mostaghimi³, Ann W Silk⁴, Chrysalyne D Schmults³, Emily Stamell Ruiz³

Affiliations

¹ Harvard Medical School, Boston, Massachusetts.
² Harvard Business School, Boston, Massachusetts.
³ Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.
⁴ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Abstract

This cross-sectional study weighs the proportional associations of rising drug costs and use with increased Medicare Part D spending for a cohort of oral anticancer drugs used from 2013 through 2017.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antineoplastic Agents* / therapeutic use
Drug Costs
Drugs, Generic
Health Expenditures
Humans
Medicare Part D*
Prescription Drugs*
United States

Substances

Antineoplastic Agents
Drugs, Generic
Prescription Drugs